Skip to content

Clinical trials

Febrile Neutropenia trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Febrile Neutropenia Phase: Not applicable Clear all

29 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20102
20121
20151
20162
20171
20181
20202
20212
20224
20232
20241
20256
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed12
Unknown status5
Not yet recruiting4
Recruiting3
Terminated2
Withdrawn2
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Peter MacCallum Cancer Centre, Australia2
Sichuan Huiyu Pharmaceutical Co., Ltd2
Assistance Publique - Hôpitaux de Paris1
Case Comprehensive Cancer Center1
Centre Hospitalier Universitaire de la Réunion1
Ciusss de L'Est de l'Île de Montréal1
Federal University of Minas Gerais1
Fondazione IRCCS Policlinico San Matteo di Pavia1
Hospital Infantil de Mexico Federico Gomez1
IDION Inc.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Febrile Neutropenia29
Neoplasms7
Neutropenia4
Hematologic Neoplasms3
Invasive Fungal Infections3
Sepsis3
Fever2
Leishmaniasis, Visceral2
Bacterial Infections1
Breast Carcinoma In Situ1

Trials

Showing 51 to 29 of 29. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.